Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort

European Journal of Cancer

Volumn 49, Issue 9, 2013, Pages 2134-2142

  Iacovelli, Roberto ^a   Cartenì, Giacomo ^b   Sternberg, Cora N ^c   Milella, Michele ^d   Santoni, Matteo ^e   Di Lorenzo, Giuseppe ^f   Ortega, Cinzia ^g   Sabbatini, Roberto ^h   Ricotta, Riccardo ⁱ   Messina, Caterina ^j   Lorusso, Vito ^k   Atzori, Francesco ^l   De Vincenzo, Fabio ^m   Sacco, Cosimo ⁿ   Boccardo, Francesco ^o   Valduga, Francesco ^p   Massari, Francesco ^q   Baldazzi, Valentina ^r   Cinieri, Saverio ^s   Mosca, Alessandra ^t   Ruggeri, Enzo Maria ^u   Berruti, Alfredo ^v   Cerbone, Linda ^c   Procopio, Giuseppe ^w   more..

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^e UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^g CANDIOLO CANCER INSTITUTE   (Italy)

^h UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

ⁱ OSPEDALE NIGUARDA CA GRANDA   (Italy)

^j OSPEDALI RIUNITI   (Italy)

^k NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^l Nuova Casa di Cura   (Italy)

^m HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

ⁿ SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^o UNIVERSITY OF GENOA   (Italy)

^p SANTA CHIARA HOSPITAL   (Italy)

^q UNIVERSITY OF VERONA   (Italy)

^r SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^s A Perrino Hospital   (Italy)

^t University Hospital Maggiore della Carita   (Italy)

^u BELCOLLE HOSPITAL   (Italy)

^v UNIVERSITY OF BRESCIA   (Italy)

^w NATIONAL CANCER INSTITUTE   (Italy)

more..

Author keywords

Axitinib; Bevacizumab; Everolimus; Renal cell carcinoma; Sequential therapy; Sorafenib; Sunitinib; Survival; Temsirolimus; Third line

Indexed keywords

AXITINIB; BEVACIZUMAB; EVEROLIMUS; INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN INHIBITOR;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; DRUG EFFICACY; FEMALE; HUMAN; ITALY; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84877703634     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.02.032     Document Type: Article

References (27)

1. J.S. Lam, J.T. Leppert, A.S. Belldegrun, and R.A. Figlin Novel approaches in the therapy of metastatic renal cell carcinoma World J Urol 23 2005 202 212
2. J.A. Garcia, and B.I. Rini Recent progress in the management of advanced renal cell carcinoma CA Cancer J Clin 57 2007 112 125
3. L.C. Harshman, W. Xie, and G.A. Bjarnason Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study Lancet Oncol 13 2012 927 935
4. A.Z. Dudek, J. Zolnierek, A. Dham, B.R. Lindgren, and C. Szczylik Sequential therapy with sorafenib and sunitinib in renal cell carcinoma Cancer 115 2009 61 67
5. C. Porta, G. Procopio, and G. Cartenì Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases BJU Int 108 2011 250 257
6. E. Calvo, A. Ravaud, and J. Bellmunt What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI? Cancer Treat Rev 2012 [Epub ahead of print]
7. J. Busch, C. Seidel, and B. Erber Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma Eur Urol 2012 10.1016/j.eururo.2012.09.004 pii: S0302-2838(12)01027-5
8. H. Miyake, Y. Kusuda, K.I. Harada, I. Sakai, and M. Fujisawa Third-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma Int J Clin Oncol 2011 [Epub ahead of print]
9. G. Di Lorenzo, C. Buonerba, and P. Federico Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma Eur Urol 58 2010 906 911
10. R.J. Motzer, M. Mazumdar, J. Bacik, W. Berg, A. Amsterdam, and J. Ferrara Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol 17 1999 2530 2540
11. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
12. R.J. Motzer, B. Escudier, and S. Oudard Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 2010 4256 4265
13. B.I. Rini, B. Escudier, and P. Tomczak Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Lancet 378 2011 1931 1939
14. T. Hutson, B. Escudier, and E. Esteban Temsirolimus vs. sorafenib as second line therapy in metastatic renal cell carcinoma: results from the INTORSECT trial Ann Oncol 23 Suppl. 9 2012 LBA22PR
15. C. Porta Entropy increases in kidney cancer treatment, but a bit of simplicity may emerge from chaos Eur Urol 60 2011 1171 1172
16. R. Iacovelli, A. Palazzo, and P. Trenta Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment Am J Clin Oncol 2013 [Epub ahead of print]
17. D.Y. Heng, W. Xie, and M.M. Regan Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794 5799
18. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon-alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
19. B. Escudier, A. Pluzanska, and P. Koralewski Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2007 2103 2111
20. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear cell renal-cell carcinoma N Engl J Med 356 2007 125 134
21. B. Escudier, C. Szczylik, and T.E. Hutson Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 1280 1289
22. R.J. Motzer, D. Nosov, and T. Eisen Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: results from a phase III randomized, open-label, multicenter trial J Clin Oncol 30 Suppl.; abstr. 4501 2012
23. J. Busch, C. Seidel, and C. Kempkensteffen Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors Eur Urol 60 2011 1163 1170
24. M.M. Vickers, T.K. Choueiri, and M. Rogers Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy Urology 76 2010 430 434
25. D.Y. Heng, M.J. MacKenzie, and U.N. Vaishampayan Primary anti-VEGF-refractory metastatic renal cell carcinoma (mRCC): clinical characteristics, risk factors, and subsequent therapy J Clin Oncol 29 Suppl. 7; abstr. 305 2011
26. G. Procopio, E. Verzoni, R. Iacovelli, V. Guadalupi, F. Gelsomino, and R. Buzzoni Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience Expert Rev Anticancer Ther 11 2011 1631 1640
27. F. Stenner, R. Chastonay, and H. Liewen A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma Oncology 82 2012 333 340